Brief: Telomir Pharmaceuticals- In Vitro Data Shows Telomir-1 Targets Additional Histone Demethylases - SEC Filing
18/09/2025 12:53
Sept 18 (Reuters) - Telomir Pharmaceuticals Inc TELO.O: TELOMIR PHARMACEUTICALS INC - IN VITRO DATA SHOWS TELOMIR-1 TARGETS ADDITIONAL HISTONE DEMETHYLASES - SEC FILING Source text: [ID:n0001493152-25-013970] Further company coverage: TELO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Telomir Pharmaceuticals
See all newsBrief: Telomir Pharmaceuticals - Alan Weichselbaum To Step Down As CFO Effective June 6, 2026 - SEC Filing
Brief: Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality In Human Triple-Negative Breast Cancer Models
Brief: Telomir Pharmaceuticals Telomir-1 Significantly Reduced Tumor Growth And Metastases
Brief: Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer’S “Kill-And-Clean” Defense Systems In An Aggressive Prostate Cancer Model
U.S. STOCKS ON THE MOVE-InterDigital, Scholar Rock, Live Nation